Specific traits at the time of diagnosis, including symptoms and lung function status, may predict morbidity and mortality in people with scleroderma, a nine-year follow-up study shows. The age and gender of the patient, type of scleroderma, presence of pulmonary fibrosis or hypertension, and lung function status are among…
News
Magnetic resonance imaging (MRI), a medical technique used to form detailed pictures of the inside of our bodies, has the potential to detect and diagnose abnormalities in the hearts of patients with scleroderma, a study suggests. According to researchers involved in the study, MRI identified abnormalities in the hearts of…
Treatment with Corbus Pharmaceuticals’ investigative therapy lenabasum (formerly known as anabasum) significantly improves the symptoms of diffuse cutaneous systemic sclerosis in a Phase 2 open-label extension study. The latest results from the trial were recently discussed at the 2018 Annual European Congress of Rheumatology (EULAR) held in Amsterdam,…
Genes and microRNAs that are a part of cancer-promoting signaling pathways are also overly active in systemic sclerosis (SSc) patients, possibly predisposing them to malignancies, a study reports. The study, “Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures,” was published in the journal…
Approximately 85 percent of Canadians with pulmonary arterial hypertension (PAH) and systemic sclerosis (SSc) now have access to Actelion’s therapy Uptravi (selexipag) through the country’s publicly funded prescription system. This action follows the conclusion of negotiations about the drug’s price by the pan-Canadian Pharmaceutical Alliance (pCPA) —…
High-intensity exercise of the arms, or arm cranking, may improve blood circulation in scleroderma patients by increasing the dilation of blood vessels (vasodilation) and the amount of oxygen consumed in the muscles, according to researchers. Cycling, an exercise for the legs, also increases muscles’ oxygen consumption, but was not…
Treatment with Opsumit (macitentan) and Esbriet (pirfenidone) provided stable improvements in a scleroderma patient with interstitial pneumonia and borderline pulmonary arterial hypertension (PAH), according to a Japanese case report. The study, “Systemic scleroderma-related interstitial pneumonia associated with borderline pulmonary arterial hypertension,” was published…
Blood serum levels of the protein CD163 may be a potential biomarker to identify patients with systemic sclerosis, according to new research from France. The study, “Soluble CD163 as a Potential Biomarker in Systemic Sclerosis,” was published in the journal Disease Markers. Systemic sclerosis…
As President Trump signed the recently passed Right to Try legislation into law in a White House ceremony, Jordan McLinn of Indianapolis tried twice to embrace him. The third time, 9-year-old Jordan finally got the hug he wanted — as well as a kiss on the forehead. The video of…
High levels of a blood protein called CC16 predict a higher likelihood of lung disease worsening in patients with systemic sclerosis (SSc), according to researchers. Their study, “High Baseline Serum Clara Cell 16 kDa Predicts Subsequent Lung Disease…
Recent Posts
- Abnormal fatty acid metabolism may play role in scleroderma: Analysis
- Cosmetic laser therapy could be repurposed for localized scleroderma
- Antibody levels may help reflect quality of life in people with scleroderma
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma